Adaptor CAR Platforms-Next Generation of T Cell-Based Cancer Immunotherapy

被引：55

作者：

Arndt, Claudia ^{[1
,2
]}

Fasslrinner, Frederick ^{[3
]}

Loureiro, Liliana R. ^{[1
,2
,4
,5
,6
]}

Koristka, Stefanie ^{[1
,2
]}

Feldmann, Anja ^{[1
,2
]}

Bachmann, Michael ^{[1
,2
,4
,5
,6
]}

机构：

[1] Helmholtz Zentrum Dresden Rossendorf HZDR, Inst Radiopharmaceut Canc Res, D-01328 Dresden, Germany

[2] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Tumor Immunol Univ Canc Ctr UCC, D-01307 Dresden, Germany

[3] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Fac Med, Med Clin & Polyclin 1, D-01307 Dresden, Germany

[4] Tech Univ Dresden, Carl Gustav Carus, Natl Ctr Tumor Dis NCT, D-01307 Dresden, Germany

[5] German Canc Consortium DKTK, Partner Site Dresden, D-69120 Heidelberg, Germany

[6] German Canc Res Ctr, D-69120 Heidelberg, Germany

来源：

CANCERS | 2020年 / 12卷 / 05期

关键词：

chimeric antigen receptor (CAR); adaptor molecule; adoptive T cell therapy; cancer immunotherapy; CHIMERIC CD16-CD3-ZETA RECEPTOR; NATURAL-KILLER-CELLS; AUTOANTIGEN LA/SS-B; ADOPTIVE IMMUNOTHERAPY; EFFECTOR-CELLS; GENE; THERAPY; LYMPHOCYTES; PHARMACOKINETICS; SPECIFICITY;

D O I：

10.3390/cancers12051302

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The success of conventional chimeric antigen receptor (CAR) therapy in the treatment of refractory hematologic malignancies has triggered the development of novel exciting experimental CAR technologies. Among them, adaptor CAR platforms have received much attention. They combine the flexibility and controllability of recombinant antibodies with the power of CARs. Due to their modular design, adaptor CAR systems propose answers to the central problems of conventional CAR therapy, such as safety and antigen escape. This review provides an overview on the different adaptor CAR platforms available, discusses the possibilities and challenges of adaptor CAR therapy, and summarizes the first clinical experiences.

引用

页数：20

共 111 条

[1]

Albert Susann, 2018, Oncotarget, V9, P25597, DOI 10.18632/oncotarget.25390

[2] A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform [J].

Albert, Susann ;

Arndt, Claudia ;

Feldmann, Anja ;

Bergmann, Ralf ;

Bachmann, Dominik ;

Koristka, Stefanie ;

Ludwig, Florian ;

Ziller-Walter, Pauline ;

Kegler, Alexandra ;

Gaertner, Sebastian ;

Schmitz, Marc ;

Ehninger, Armin ;

Cartellieri, Marc ;

Ehninger, Gerhard ;

Pietzsch, Hans-Juergen ;

Pietzsch, Jens ;

Steinbach, Joerg ;

Bachmann, Michael .

ONCOIMMUNOLOGY, 2017, 6 (04)

[3] The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma [J].

Ali, Sahra ;

Kjeken, Rune ;

Niederlaender, Christiane ;

Markey, Greg ;

Saunders, Therese S. ;

Opsata, Mona ;

Moltu, Kristine ;

Bremnes, Bjorn ;

Gronevik, Eirik ;

Muusse, Martine ;

Hakonsen, Gro D. ;

Skibeli, Venke ;

Kalland, Maria Elisabeth ;

Wang, Ingrid ;

Buajordet, Ingebjorg ;

Urbaniak, Ania ;

Johnston, John ;

Rantell, Khadija ;

Kerwash, Essam ;

Schuessler-Lenz, Martina ;

Salmonson, Tomas ;

Bergh, Jonas ;

Gisselbrecht, Christian ;

Tzogani, Kyriaki ;

Papadouli, Irene ;

Pignatti, Francesco .

ONCOLOGIST, 2020, 25 (02) :E321-E327

[4] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J].

Ali, Syed Abbas ;

Shi, Victoria ;

Maric, Irina ;

Wang, Michael ;

Stroncek, David F. ;

Rose, Jeremy J. ;

Brudno, Jennifer N. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Hansen, Brenna G. ;

Fellowes, Vicki S. ;

Hakim, Frances T. ;

Gress, Ronald E. ;

Kochenderfer, James N. .

BLOOD, 2016, 128 (13) :1688-1700

[5] CAR T cells specific for CD19 can be redirected to kill CD19 negative tumors [J].

Ambrose, Christine ;

Su, Lihe ;

Wu, Lan ;

Lobb, Roy R. ;

Rennert, Paul D. .

CANCER RESEARCH, 2017, 77

[6] Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives [J].

Andreesen, R ;

Hennemann, B ;

Krause, SW .

JOURNAL OF LEUKOCYTE BIOLOGY, 1998, 64 (04) :419-426

[7] Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].

Arai, S. ;

Meagher, R. ;

Swearingen, M. ;

Myint, H. ;

Rich, E. ;

Martinson, J. ;

Klingemann, H. .

CYTOTHERAPY, 2008, 10 (06) :625-632

[8] UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells [J].

Arndt, Claudia ;

Loureiro, Liliana R. ;

Feldmann, Anja ;

Jureczek, Justyna ;

Bergmann, Ralf ;

Mathe, Domokos ;

Hegedues, Nikolett ;

Berndt, Nicole ;

Koristka, Stefanie ;

Mitwasi, Nicola ;

Fasslrinner, Frederick ;

Lamprecht, Chris ;

Kegler, Alexandra ;

Hoffmann, Anja ;

Bartsch, Tabea ;

Koeseer, Ayse Sedef ;

Egan, Gary ;

Schmitz, Marc ;

Horejsi, Vaclav ;

Krause, Mechthild ;

Dubrovska, Anna ;

Bachmann, Michael .

ONCOIMMUNOLOGY, 2020, 9 (01)

[9] A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR [J].

Arndt, Claudia ;

Feldmann, Anja ;

Koristka, Stefanie ;

Schaefer, Martin ;

Bergmann, Ralf ;

Mitwasi, Nicola ;

Berndt, Nicole ;

Bachmann, Dominik ;

Kegler, Alexandra ;

Schmitz, Marc ;

Puentes-Cala, Edinson ;

Andres Soto, Javier ;

Ehninger, Gerhard ;

Pietzsch, Jens ;

Liolios, Christos ;

Wunderlich, Gerd ;

Kotzerke, Joerg ;

Kopka, Klaus ;

Bachmann, Michael .

ONCOIMMUNOLOGY, 2019, 8 (11)

[10]

Bachmann Dominik, 2018, Oncotarget, V9, P7487, DOI 10.18632/oncotarget.23556

← 1 2 3 4 5 6 7 8 9 10 →